Lopinavir/Ritonavir

洛匹那韦/利托那韦

Report date: 2026/05/25 20:02:40

Base Information

Drug NameLopinavir/Ritonavir
Drug Alias Name利托那韦/洛匹那韦Ritonavir and LopinavirLopinavir and Ritonavir利托那韦洛匹那韦洛匹那韦利托那韦 +[13] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionHuman immunodeficiency virus type 1 protease inhibitors
TargetsHuman immunodeficiency virus type 1 protease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHematologic Neoplasms +[7] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2000/09/15
Country/TerritoryCanadaZambiaUnited States +[23] 
CombinationsYes Ritonavir
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesDaré Bioscience IncAbbvie Inc +[4] 
Inactive CompaniesBristol Myers Squibb SrlcompanyRadboud University Medical CenterPenta Global Foundation Pte Ltd +[11] 
Active IndicationsPapillomavirus InfectionsHIV Infections
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursHematologic Neoplasms +[5] 

Other Information

ATC CodeJ05AR10
Related LinksWikipediaKEGG